HPQ
HP Inc.
HPQ trails on the overall score without a compensating advantage in the available component scores.
NVDA
NVIDIA Corporation
NVDA has the edge over HPQ overall, supported by stronger valuation and stronger modeled upside.
HPQ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Healthy |
HPQ's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
HPQ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.3x | $19.05 | -34% |
| Forward | 9.3x | $28.88 | — |
| Fair | 9.8x | $25.65 | -11% |
| Current | 11x | $28.88 | — |
| Expensive | 12x | $31.53 | +9.2% |
Historical ranges are pointers, not guarantees.
HPQ's PE is in its expensive range at 11x. If earnings grow as analysts expect, today's price would be 9.3x next year's earnings, in its fair range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over HPQ in the historical PE scenario, which offers more potential upside but is not a forecast.
HPQ Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect HPQ's earnings to grow, with its revenue and profitability holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
HPQ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.11 | +19% |
| Q3 2026 | $2.62 | -4.4% |
| Q2 2026 | $2.71 | +4.6% |
| Q1 2026 | $2.64 | -5% |
| Q4 2025 | $2.65 | -5.7% |
| Q3 2025 | $2.74 | -3.9% |
| Q2 2025 | $2.59 | -13% |
| Q1 2025 | $2.78 | -19% |
| Q4 2024 | $2.81 | -15% |
HPQ's earnings per share have fallen from their peak: $2.62 over the past year, against $5.61 in mid-2022.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over HPQ on earnings, with more consistent year-over-year improvement.
HPQ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.7B | +13% |
| Q2 2026 | $14.4B | +9% |
| Q1 2026 | $14.4B | +6.9% |
| Q4 2025 | $14.6B | +4.2% |
| Q3 2025 | $13.9B | +3.1% |
| Q2 2025 | $13.2B | +3.3% |
| Q1 2025 | $13.5B | +2.4% |
| Q4 2024 | $14.1B | +1.7% |
HPQ's revenue has grown year over year for nine quarters in a row: $15.7B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | +0.6 points |
| Q2 2026 | 4.3% | -0.7 points |
| Q1 2026 | 5.3% | -1 points |
| Q4 2025 | 6.5% | -0.5 points |
| Q3 2025 | 5.1% | -1.8 points |
| Q2 2025 | 5% | -2.5 points |
| Q1 2025 | 6.3% | -0.8 points |
| Q4 2024 | 7% | -0.3 points |
HPQ's operating margin was 5.7% last quarter, up 0.6 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over HPQ on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over HPQ on profitability, with a higher operating margin.
HPQ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +7.1% |
| Q2 2026 | $756M | +$901M |
| Q1 2026 | $150M | +108% |
| Q4 2025 | $1.4B | -2.9% |
| Q3 2025 | $1.4B | +15% |
| Q2 2025 | -$145M | -131% |
| Q1 2025 | $72M | +$109M |
| Q4 2024 | $1.5B | -19% |
HPQ still generates free cash flow, though less than at its 2021 peak: $3.9B over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over HPQ on cash flow, with more consistent year-over-year improvement.
HPQ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +2M shares |
| 1 year | -2.8% | -27M shares |
| 3 years | -7.5% | -75M shares |
| 5 years | -23% | -272M shares |
| Available history | -39% | -597M shares |
HPQ has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300M |
| Q2 2026 | $100M |
| Q1 2026 | $325M |
| Q4 2025 | $500M |
| Q3 2025 | $200M |
| Q2 2025 | $100M |
| Q1 2025 | $100M |
| Q4 2024 | $900M |
HPQ spent $1.2B buying back its own shares over the past year, down 5.8% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
HPQ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | 1.4x | Healthy |
HPQ's net debt is about 1.2 years of its operating earnings (EBITDA), down from 1.6 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over HPQ on leverage, with a lower net debt burden relative to earnings.
HPQ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.2 | Neutral |
| Stochastic | 23.8 | Neutral |
HPQ's weekly RSI is 51 (neutral) and its Stochastic is 24 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
HPQ PE vs Technology Sector
| Metric | HPQ | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 60% below |
| PE % | 69 | 35 | 34 pts above |
HPQ has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
HPQ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.1% below |
| 20 week MA | $29.5 | 2.2% below |
| 50 week MA | $24.7 | 17% above |
| 100 week MA | $26.2 | 10% above |
| 200 week MA | $28.8 | 0.5% above |
HPQ has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
HPQ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.5 | $24.3 | +18% |
| 2021 | $24.3 | $37.7 | +55% |
| 2022 | $37.7 | $26.8 | -29% |
| 2023 | $26.8 | $30.1 | +12% |
| 2024 | $30.1 | $33.3 | +11% |
| 2025 | $33.3 | $23.3 | -30% |
| 2026 YTD | $23.3 | $28.9 | +24% |
HPQ has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.